B&K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline
B&K Corporation Limited (HKG: 2396) officially listed on the Hong Kong Stock Exchange today, offering...
IPO
Juncell Therapeutics Files for HKEX IPO, Pioneering Chemo‑Free TIL Therapy for Solid Tumors
Shanghai Juncell Therapeutics Co., Ltd. (“JunCell Biologics”) released its prospectus, announcing its intention to list...
Shanghai Bao Pharma IPO HKEX Raises HK$1 Billion for Biotech Pipeline
Shanghai Bao Pharmaceuticals Co., Ltd. (HKG: 2659) successfully listed on the Hong Kong Stock Exchange...
3SBio’s Mandi Spin-Off Targets HKEX IPO as Hair Health Leader
3SBio Inc. (HKG: 1530) announced plans to spin off its consumer healthcare subsidiary Mandi International...
Sichuan Biokin Launches on HKEX, Raises HK$3.3 B in $389/Share Offering – A Milestone for China’s Biotech
China’s Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced its successful initial public offering (IPO)...
BrightGene Submits HKEX Prospectus, Aiming for Main‑Board Listing
BrightGene Bio‑Medical Technology Co., Ltd. (SHA: 688166) filed its prospectus with the Stock Exchange of...
Fosun Pharmaceutical Announces Spin‑Off and HK Listing of Adgenvax
Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) today disclosed its intention to spin‑off...
Wuhan Healthgen Announces STAR Market IPO of ORYZOGEN Shares
Wuhan Healthgen Biotechnology Corp. (SHA: 688765) today announced that the Shanghai Stock Exchange has approved...
I‑Mab Announces Global Transformation, NovaBridge Rebranding, and $37 M Acquisition of VIS‑101
I‑MAB Biopharma (NASDAQ: IMAB), a public company under the CBC Group, today revealed a strategic...
AstraZeneca Announces Dual‑Market Direct Listing on NYSE, Harmonising Global Share Structure
AstraZeneca plc (AZ; NASDAQ: AZN) has unveiled a plan to standardise its share‑listing structure across...
Biocytogen Eyes A‑Share Listing on Shanghai’s STAR Market to Fund Preclinical R&D Growth
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has filed a prospectus announcing plans to seek...
Shenzhen Mindray Eyes $1 B+ Hong Kong IPO With Huatai, JPMorgan On Board
Shenzhen Mindray Bio‑Medical Electronics Co. has confirmed that Huatai Securities and JPMorgan Chase & Co. are the...
GenFleet Therapeutics Surges onto Hong Kong Main Board, Raising HK$1.58 B
China‑based GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) completed a successful initial public offering (IPO) on the...
Dongcheng Pharma to Spin‑Off Lannacheng for HK Main Board Listing – Radiopharma Focus
Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675) announced that it will spin off its...
Shanghai Bao Pharma Files for Hong Kong IPO, Aiming to Boost Biologics Development
Shanghai Bao Pharmaceuticals Co. Ltd., a company leveraging synthetic biology to develop recombinant biologics, submitted...
Minghui Pharmaceutical Secures $131M Pre-IPO Funding Led by OrbiMed and Qiming Ventures
China-based Minghui Pharmaceutical Inc. announced the successful completion of a $131 million Pre-IPO financing round....
Guangzhou Innogen Pharmaceuticals Launches H-Share Global Offering in Hong Kong
China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd. (HKG: 2591) officially launched its H-share global offering...
TenNor Therapeutics Submits Listing Application to Hong Kong Stock Exchange Main Board
China-based TenNor Therapeutics (Suzhou) Limited announced the submission of its listing application to the Main...
Hunan Mabgeek Biotech Files for Hong Kong IPO to Expand Innovative Biologics Pipeline
China-based Hunan Mabgeek Biotech Co., Ltd has submitted an application to the Hong Kong Stock...
China’s WeiMai Plans Hong Kong IPO to Expand AI-Powered Healthcare Services
China-based WeiMai Inc. plans to make an initial public offering (IPO) to the Hong Kong...